Non-ketotic hyperglycinaemia is an autosomal recessive disorder of glycine metabolism caused by a defect in the glycine cleavage system. Affected neonates present with lethargy, feeding difficulty, hypotonia, apnoea, poorly controlled convulsions and coma. Four cases are reported, three of whom died in the neonatal period. The fourth case was treated with dextromethorphan and sodium benzoate. He survived with neurodevelopmental delay but is now almost seizure-free.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1179/027249304225019172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nonketotic hyperglycinemia (NKH), also known as glycine encephalopathy, is a rare inherited neurometabolic disorder caused by a deficiency in the glycine cleavage enzyme system (GCS), leading to the pathological accumulation of glycine in blood and cerebrospinal fluid (CSF). This case report details a neonate presenting with central apnea, profound hypotonia, and refractory seizures, alongside prenatal findings of polyhydramnios and hiccup-like fetal movements, all strongly suggestive of severe NKH. Diagnostic evaluation confirmed markedly elevated glycine levels in serum and CSF, with a CSF-to-plasma glycine ratio exceeding 0.
View Article and Find Full Text PDFAnesthetic management using desflurane and nitrous oxide in a child with non-ketotic hyperglycinemia: a case report.
JA Clin Rep
December 2024
Department of Anesthesiology, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori, Chuo-Ku, Niigata, 951-8520, Japan.
Background: Non-ketotic hyperglycinemia (NKH) is a rare autosomal recessive disorder caused by defects in the glycine cleavage system, leading to elevated glycine levels in the central nervous system. NKH manifests in various forms, with the neonatal type being the most severe and often associated with high mortality and significant neurological impairment. This case report highlights the successful uses of desflurane and nitrous oxide for anesthetic management in a patient with NKH.
View Article and Find Full Text PDFThe role of NMDA-receptor type glutamatergic antagonists dextromethorphan or ketamine in the treatment of nonketotic hyperglycinemia: A critical reassessment.
Mol Genet Metab
November 2024
Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado, Aurora, CO 80045, USA. Electronic address:
The recognition of glycine as an endogenous ligand at the allosteric activation site of the NMDA-type glutamatergic receptor led to the assumption that the excess glycine in nonketotic hyperglycinemia would result in overactivation of these receptors, and of the proposed use of inhibitors such as dextromethorphan or ketamine as a therapeutic agent. Years later it was recognized that these same receptors have an alternative endogenous activator d-serine, which is markedly decreased in nonketotic hyperglycinemia. This may result in underactivation of these NMDA-type glutamatergic receptors, challenging the earlier hypothesis.
View Article and Find Full Text PDFCase report: Unveiling genetic and phenotypic variability in Nonketotic hyperglycinemia: an atypical early onset case associated with a novel variant.
Front Genet
September 2024
Service de Neurologie Pédiatrique, CHU Bordeaux, University Bordeaux, CNRS, INCIA, UMR 5287, NRGen Team, Bordeaux, France.
Article Synopsis
- * A new case of NKH was identified involving a child with a unique genetic variant in the GLRX5 gene that led to significant neurological problems, confirmed through MRI and cerebrospinal fluid analysis.
- * The child, who experienced a rapid decline in health, passed away at four months old, demonstrating that this case was more severe than previously documented instances of GLRX5-related NKH, emphasizing the importance of genetic factors in the disorder's severity and symptoms.
[Epilepsy and inborn errors of metabolism].
Rev Neurol
September 2024
Hospital Universitario Miguel Servet, Zaragoza, España.
Article Synopsis
- - Epilepsy frequently occurs in metabolic disorders, showing varied severity and treatment response, highlighting the importance of understanding its characteristics in these conditions.
- - A study reviewed cases of epilepsy linked to different metabolic diseases, revealing that two-thirds of molybdenum cofactor deficiency cases had neonatal epileptic encephalopathy, while other conditions displayed diverse patterns of incidence and treatment efficacy.
- - Accurate diagnosis of metabolic epilepsy relies on clinical indicators such as age of onset and treatment resistance; further research is needed for early biomarkers and effective targeted therapies despite the rising utility of genetic testing.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!